Indexing
CÁC SỐ TỪ 2011-2023
Tạp chí Y Dược Học
Abstract
Background: The Pemetrexed - Carboplatin regimen is indicated for the treatment of advanced non-squamous non-small cell lung cancer. Although the regimen is widely used worldwide, due to its cost, it is not commonly used in Vietnam, especially in the Central region.
Objectives: To evaluate the efficacy and toxicity of the pemetrexed-carboplatin regimen in patients with advanced non-squamous non-small cell lung cancer.
Methods: Prospective descriptive study on 30 patients with stage IIIB-IV non-squamous non-small cell lung cancer who received first-line chemotherapy with pemetrexed-carboplatin at Hue Central Hospital, Hue University of Medicine and Pharmacy Hospital, and Da Nang Oncology Hospital from April 2022 to June 2023.
Results: The study cohort had a mean age of 60.9 ± 12.3 years, with a male-to-female ratio of 1.1:1, and 90% of patients were diagnosed at stage IV. The objective response rate (ORR) was 33.3%, and the disease control rate (DCR) was 56.7%. The mean progression-free survival (PFS) was 9.5 ± 1.1 months, while the mean overall survival (OS) was 11.5 ± 0.9 months. The most common hematologic toxicity was anemia (60%), predominantly grade 1 - 2. Non-hematologic toxicities were mostly grade 1 - 2 and did not interfere with treatment administration.
Conclusion: The Pemetrexed–Carboplatin regimen demonstrated effective disease control and prolongation of survival in patients with advanced non-squamous non–small cell lung cancer, with a favorable safety profile.
| Published | 2026-03-30 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 1 (2026) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2026.1.1032 | |
| Keywords | Ung thư phổi không tế bào nhỏ, giai đoạn tiến xa, pemetrexed-carboplatin, hoá trị Non-small cell lung cancer, advanced stage, pemetrexed-carboplatin |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Hue Journal of Medicine and Pharmacy
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–49.
Globocan. Globocan Viet Nam 2020. 2020. 3. Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: Analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. Journal of Clinical Oncology. 2006 Jun 20;24(18_suppl):7082. Available from: https://doi. org/10.1200/jco.2006.24.18_suppl.7082.
Lê Viết Nam, Phạm Cẩm Phương. Đánh giá kết quả hóa trị phác đồ có pemetrexed trong ung thư phổi không tế bào nhỏ giai đoạn IIIB – IV tại bệnh viện Bạch Mai. Tạp Chí Y Học Việt Nam. 2021;(506):153–7.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA, Clin M, et al. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship [Internet]. Vol. 83, Mayo Clin Proc. 2008. Available from: www.
mayoclinicproceedings.com.
Bộ Y tế Việt Nam. Hướng dẫn chẩn đoán và điều trị ung thư phổi không tế bào nhỏ. 2018.
Kristina Gregory N, Miranda Hughes O, Aisner DL, Akerley W, Bauman JR, Bruno DS, et al. NCCN Guidelines Version 3.2023 Non-Small Cell Lung Cancer Continue NCCN Guidelines Panel Disclosures [Internet]. 2023. Available from: https://www.nccn.org/home/member
Cohen MH, Johnson JR, Wang YC, Sridhara R, Pazdur R. FDA Drug Approval Summary: Pemetrexed for Injection (Alimta®) for the Treatment of Non-Small Cell Lung Cancer. Oncologist. 2005 Jun 1;10(6):363–8.
Trần Mạnh Hoàng, Đỗ Kim Quế, Nguyễn Thị Hồng. Đánh giá hiệu quả và an toàn của phác đồ có pemetrexed ở bệnh nhân ung thư phổi không tế bào nhỏ không gai giai đoạn IV. Journal of Clinical Medicine- Hue Central Hospital. 2022 Aug 26;(82).
Mai Trọng Khoa, Phạm Cẩm Phương, Nguyễn Đức Luân. Đánh giá hiệu quả điều trị của phác đồ pemetrexed - platinum trong bệnh ung thư phổi tại bệnh viện Bạch Mai. Tạp Chí Y Học Việt Nam. 2017;97–104.
Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, et al. American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology. Journal of Clinical Oncology. 2012 May 10;30(14):1715–24.
Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2014 Sep 1;25: iii27–39.
Nguyễn Thị Thái Hòa. Kết quả điều trị pemetrexed - carboplatin ung thư biểu mô tuyến của phổi giai đoạn IV ở bệnh nhân cao tuổi. Y Học Cộng Đồng. 2020; 3:13–6.
Ito M, Horita N, Nagashima A, Kaneko T. Carboplatin plus pemetrexed for the elderly incurable chemo-naive nonsquamous non–small cell lung cancer: Meta-analysis. Asia Pac J Clin Oncol. 2019 Apr 1;15(2): e3–10.
Metro G, Chiari R, Mare M, Giannarelli D, Tofanetti FR, Minotti V, et al. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: A retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol. 2011 Dec;68(6):1405–12.
Zinner RG, Fossella F V., Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer. 2005 Dec 1;104(11):2449–56.
Hàn Thị Thanh Bình. Nghiên cứu điều trị ung thư phổi không tế bào nhỏ giai đoạn IIB, IV bằng hóa trị phác đồ cisplatin kết hợp với paclitaxel hoặc etoposide. Hà Nội; 2018.
Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, et al. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non
small cell lung cancer. Journal of Thoracic Oncology. 2011 Nov;6(11):1907–14.
Karayama M, Inui N, Kuroishi S, Yokomura K, Toyoshima M, Shirai T, et al. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study. Cancer Chemother Pharmacol. 2013 Aug 27;72(2):445–52.
Nguyễn Thị Thái Hòa, Mai Thanh Huyền. Kết quả điều trị bước hai pemetrexed – carboplatin ung thư phổi không tế bào nhỏ sau kháng thứ phát thuốc ức chế tyrosine kinase. VietNam Medical Journal [Internet]. 2021;45–8. Available from: https://doi.org/10.1038/s41598-